Table 3. Relationship between inhibitory immune checkpoint genes and clinicopathological characteristics.
| Gene | Affymetrix IDs | Clinicopathological characteristics | HR | 95% CI | P-value | |
|---|---|---|---|---|---|---|
| ADORA2A | 205013_s_at | Grade | I | 0.86 | 0.34–2.18 | 0.75 |
| II | 1.17 | 0.76–1.79 | 0.47 | |||
| III | 1 | 0.72–1.38 | 0.99 | |||
| ER | positive | 1.1 | 0.77–1.57 | 0.6 | ||
| negative | 0.98 | 0.62–1.54 | 0.94 | |||
| HER-2 | positive | 0.77 | 0.38–1.55 | 0.46 | ||
| negative | 0.46 | 0.18–1.2 | 0.1 | |||
| Chemotherapy history | yes | 0.76 | 0.46–1.23 | 0.26 | ||
| no | 1 | 0.71–1.42 | 0.98 | |||
| p53 status | mutant | 1.2 | 0.56–2.57 | 0.64 | ||
| wild-type | 1.67 | 0.86–3.25 | 0.13 | |||
| LAG-3 | 206486_at | Grade | I | 0.97 | 0.39–2.4 | 0.94 |
| II | 1.27 | 0.83–1.94 | 0.28 | |||
| III | 0.68 | 0.48–0.94 | 0.019 | |||
| ER | positive | 1.18 | 0.83–1.69 | 0.35 | ||
| negative | 0.7 | 0.44–1.11 | 0.12 | |||
| HER-2 | positive | 0.79 | 0.39–1.59 | 0.51 | ||
| negative | 0.66 | 0.28–1.57 | 0.34 | |||
| Chemotherapy history | yes | 0.71 | 0.44–1.17 | 0.18 | ||
| no | 1.18 | 0.83–1.67 | 0.35 | |||
| p53 status | mutant | 0.73 | 0.34–1.56 | 0.41 | ||
| wild-type | 1.52 | 0.79–2.93 | 0.21 | |||
| TIM-3 | 235458_at | Grade | I | 0.65 | 0.17–2.48 | 0.64 |
| II | 1.25 | 0.4–3.96 | 0.7 | |||
| III | 0.66 | 0.4–1.1 | 0.11 | |||
| ER | positive | 1.63 | 0.76–3.52 | 0.21 | ||
| negative | 0.45 | 0.21–0.94 | 0.029 | |||
| HER-2 | positive | / | / | / | ||
| negative | 0.92 | 0.32–2.62 | 0.87 | |||
| Chemotherapy history | yes | 0.78 | 0.28–2.16 | 0.63 | ||
| no | / | / | / | |||
| p53 status | mutant | 0.65 | 0.17–2.48 | 0.53 | ||
| wild-type | / | / | / | |||
| PD1 | 207634_at | Grade | I | 0.54 | 0.21–1.36 | 0.18 |
| II | 1.07 | 0.7–1.65 | 0.75 | |||
| III | 0.84 | 0.61–1.17 | 0.3 | |||
| ER | positive | 0.93 | 0.65–1.33 | 0.69 | ||
| negative | 0.71 | 0.45–1.12 | 0.14 | |||
| HER-2 | positive | 1.03 | 0.5–2.1 | 0.94 | ||
| negative | 0.46 | 0.16–1.27 | 0.12 | |||
| Chemotherapy history | yes | 1.35 | 0.81–2.25 | 0.24 | ||
| no | 0.77 | 0.53–1.1 | 0.14 | |||
| p53 status | mutant | 1.47 | 0.63–3.43) | 0.37 | ||
| wild-type | 1.08 | 0.57–2.06) | 0.81 | |||
| CTLA-4 | 236341_at | Grade | I | 0.44 | 0.04–4.86 | 0.49 |
| II | 1.11 | 0.36–3.44 | 0.86 | |||
| III | 0.43 | 0.25–0.73 | 0.0013 | |||
| ER | positive | 0.86 | 0.41–1.84 | 0.7 | ||
| negative | 0.56 | 0.27–1.16 | 0.12 | |||
| HER-2 | positive | / | / | / | ||
| negative | 0.73 | 0.25–2.09 | 0.55 | |||
| Chemotherapy history | yes | 0.31 | 0.1–0.96) | 0.032 | ||
| no | / | / | / | |||
| p53 status | mutant | 0.25 | 0.05–1.18 | 0.058 | ||
| wild-type | / | / | / | |||
| IDO1 | 210029_at | Grade | I | 0.56 | 0.2–1.41 | 0.21 |
| II | 1.39 | 0.9–2.13 | 0.134 | |||
| III | 0.53 | 0.37–0.74 | 0.00021 | |||
| ER | positive | 1.04 | 0.73–1.48 | 0.82 | ||
| negative | 0.63 | 0.39–1 | 0.046 | |||
| HER-2 | positive | 0.46 | 0.22–0.95 | 0.032 | ||
| negative | 1.01 | 0.43–2.39 | 0.98 | |||
| Chemotherapy history | yes | 0.78 | 0.48–1.28 | 0.33 | ||
| no | 1.07 | 0.75–1.51 | 0.72 | |||
| p53 status | mutant | 0.81 | 0.38–1.74 | 0.59 | ||
| wild-type | 1.15 | 0.6–2.19 | 0.67 | |||
| B7-H3 | 224859_at | Grade | I | 2.14 | 0.19–23.79 | 0.53 |
| II | 1.16 | 0.38–3.61 | 0.79 | |||
| III | 1.34 | 0.8–2.23 | 0.25 | |||
| ER | positive | 2.13 | 0.96–4.73 | 0.059 | ||
| negative | 1.11 | 0.55–2.25 | 0.77 | |||
| HER-2 | positive | / | / | / | ||
| negative | 2.16 | 0.72–6.48 | 0.16 | |||
| Chemotherapy history | yes | 1.04 | 0.38–2.87 | 0.94 | ||
| no | / | / | / | |||
| p53 status | mutant | 1.15 | 0.31–4.29 | 0.84 | ||
| wild-type | / | / | / | |||
| TIGIT | 240070_at | Grade | I | / | / | / |
| II | 2.48 | 0.75–8.26 | 0.13 | |||
| III | 0.55 | 0.32–0.92 | 0.022 | |||
| ER | positive | 1.07 | 0.5–2.28 | 0.85 | ||
| negative | 0.84 | 0.42-1.71 | 0.64 | |||
| HER-2 | positive | / | / | / | ||
| negative | 0.71 | 0.25–2.06 | 0.53 | |||
| Chemotherapy history | yes | 0.45 | 0.15–1.32 | 0.13 | ||
| no | / | / | / | |||
| p53 status | mutant | 0.48 | 0.12–1.92 | 0.29 | ||
| wild-type | / | / | / | |||
| CD80 | 1554519_at | Grade | I | / | / | / |
| II | 0.77 | 0.24–2.42 | 0.65 | |||
| III | 0.34 | 0.19–0.61 | 0.00013 | |||
| ER | positive | 0.76 | 0.36–1.63 | 0.48 | ||
| negative | 0.38 | 0.18–0.8 | 0.0087 | |||
| HER-2 | positive | / | / | / | ||
| negative | 0.53 | 0.18–1.59 | 0.25 | |||
| Chemotherapy history | yes | 0.52 | 0.81–1.51 | 0.22 | ||
| no | / | / | / | |||
| p53 status | mutant | 0.46 | 0.11–1.84 | 0.26 | ||
| wild-type | / | / | / | |||
| CD86 | 205685_at | Grade | I | 0.91 | 0.37–2.24 | 0.84 |
| II | 0.92 | 0.6–1.42 | 0.72 | |||
| III | 0.79 | 0.57–1.1 | 0.16 | |||
| ER | positive | 0.9 | 0.63–1.28 | 0.57 | ||
| negative | 1.09 | 0.7–1.72 | 0.7 | |||
| HER-2 | positive | 0.79 | 0.39–1.58 | 0.5 | ||
| negative | 0.97 | 0.41–2.28 | 0.94 | |||
| Chemotherapy history | yes | 0.91 | 0.56–1.48 | 0.69 | ||
| no | 1.01 | 0.72–1.44 | 0.93 | |||
| p53 status | mutant | 0.61 | 0.28–1.32 | 0.21 | ||
| wild-type | 1.12 | 0.59–2.14 | 0.73 | |||